
    
      Prior to conducting any of the screening tests, the Investigator or his designee will explain
      the trial fully to the prospective patient and provide him with a copy of the Patient
      Information Leaflet/Informed Consent Form.

      If the patient is willing to participate to the trial, his given oral, free, informed and
      express consent will be collected and traced in his medical file.

      The screening questionnaire will be completed. The patient's suitability for the trial will
      be confirmed by the inclusion/exclusion criteria .

      Following completion of the Baseline Questionnaire, patients will receive the Daily
      Questionnaire. This is designed to assess if they have developed symptoms associated with
      COVID-19 infection.

      If a participant responds that they are not feeling well, a series of follow-up questions
      will be asked regarding what symptoms they are currently experiencing.

      The Daily Questionnaire will be asked of patients every day throughout the Observation Period
      of 6 months.

      At the end of the Observation Period, all patients will complete a series of questionnaires
      relating to the conduct of the study and tools employed.
    
  